Morphea: Progress to Date and the Road Ahead

The document reviewed the progress in understanding and managing morphea, an autoimmune disorder characterized by skin and soft tissue inflammation. It emphasized the need for accurate diagnosis and treatment, with current therapies including topical steroids, calcineurin inhibitors, methotrexate, and corticosteroids, while emerging treatments like mycophenolate mofetil and phototherapy showed promise. The document highlighted the importance of refining clinical outcome measures and developing patient-reported outcomes to better capture the impact of morphea. Biomarkers and imaging techniques were explored for assessing disease activity, and the potential of 3D imaging and histologic markers was noted. Despite advancements, further research was needed to improve treatment efficacy and patient quality of life.